Maqola

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. MotzerFrom Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central HospitalBernard EscudierInstitut Gustave Roussy, VillejuifRay McDermottBeth Israel Deaconess Medical CenterSaby GeorgeRoswell Park Cancer Institute, BuffaloHans J. HammersJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, BaltimoreSandhya SrinivasStanford Cancer Institute, Stanford, CAScott S. TykodiUniversity of Washington and Fred Hutchinson Cancer Research Center, SeattleJeffrey A. SosmanVanderbilt University Medical Center, NashvilleGiuseppe ProcopioFondazione Istituto Nazionale Tumori, MilanElizabeth R. PlimackFox Chase Cancer Center, PhiladelphiaDaniel CastellanoHospital Universitario 12 De Octubre, MadridToni K. ChoueiriDana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical SchoolHoward GurneyWestmead Hospital and Macquarie University, SydneyFrede DonskovAarhus University Hospital, Aarhus, DenmarkPetri BonoHelsinki University Central Hospital and University of Helsinki, HelsinkiJohn WagstaffSouth West Wales Cancer Institute and Swansea University College of Medicine, SwanseaThomas GaulerUniversity Hospital Essen of University of Duisburg–Essen, GermanyTakeshi UedaChiba Cancer Center, ChibaYoshihiko TomitaNiigata University, NiigataFabio A.B. SchutzHospital Sao Jose, Beneficencia Portuguesa de São Paulo, São PauloChristian KollmannsbergerBritish Columbia Cancer Agency, Vancouver, BC, CanadaJames LarkinRoyal Marsden Hospital, LondonAlain RavaudBordeaux University Hospital, Hôpital Saint André, BordeauxJason S. SimonBristol-Myers Squibb, LawrencevilleLi-An XuIan M. WaxmanBristol-Myers Squibb, LawrencevillePadmanee SharmaM.D. Anderson Cancer Center, University of Texas, Houston

2015en

ABI

Annotatsiya

BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1056/nejmoa1510665

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar